SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time. Event: Canac ...

SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025. Invest ...

Core Viewpoint - Ceribell, Inc. has filed complaints against Natus Medical Incorporated for patent infringement related to point-of-care EEG technology, seeking an investigation and exclusion order from the USITC to prevent the importation of infringing products [1][2]. Company Overview - Ceribell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions, having developed a novel point-of-care EEG platform [5][6]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions, and is FDA-cleared for indicating suspected seizure activity [5]. Legal Actions - Ceribell has filed a complaint with the U.S. International Trade Commission and the U.S. District Court in Delaware, alleging that Natus infringes on six of its patents related to EEG headband and electrode design [1][2]. - The company emphasizes its commitment to fair competition and the protection of its intellectual property to continue delivering innovative products [3].

CeriBell (CBLL) FY Conference June 03, 2025 10:20 AM ET Speaker0 Right. Good morning everyone. Thank you for joining us at the William Growth Stock Conference. My name is Margaret Kayser Andrew and I am the analyst here that covers Sarah Bell. There is a complete list of research disclosures and conflicts of interest at williamblair.com. But before we head off the presentation, I'll maybe start off with a thirty second pitch here. Cerabell was one of our feature stocks going into this week and it's really a ...

Company Overview - Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA-cleared for detecting suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present at the William Blair 45 Annual Growth Stock Conference [1] - The presentation is scheduled for Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time [2] - A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website [2]

CeriBell (CBLL) 2025 Conference May 14, 2025 01:55 PM ET Speaker0 From the Vice Analyst at Bank of America. I wanted to introduce our next speaker, Jane Chao, CEO of Cerebell, a newly public company. And so Jane, welcome, and you're going to go through a slide presentation. Speaker1 Thank you, Travis. I got this mic. Good. I don't need to if you can hear me well, I don't need to be in the mic. Right? Okay. Perfect. Well, good morning, everyone. Thank you for being here. I'm very excited to share our story. ...

CeriBell (CBLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations AssociateJane Chao - Co-Founder, President, CEO & DirectorScott Blumberg - Chief Financial OfficerStephanie Piazzola - VP - Equity ResearchRohin Patel - Vice PresidentJoshua Jennings - Managing DirectorJohn Young - Director - Healthcare Equity ResearchJeffrey Cohen - MD - Equity Research Conference Call Participants Margaret Kaczor Andrew - Research Analyst - Healthcare Operator thank ...

CeriBell (CBLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 thank you for standing by. At this time, I would like to welcome you to the Cerebell Q1 twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Elizabeth Spariccio, Investor Relations. Please go ahead. Speaker1 Good afternoon, and thank you all for participating in today' ...

[PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) CeriBell, Inc. reported Q1 2025 total revenue of **$20.5 million**, a **42% increase** year-over-year, with a net loss of **$12.8 million** Condensed Balance Sheet Data (in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $153,360 | $194,370 | | Total current assets | $205,420 | $217,272 | | Total assets | $213,471 | $225,412 | | **Liabilities & Equity** | | | | Total current liabilities | $11,831 | $12,989 | | Total liabilities | $32,590 | $34,247 | | Total stockholders' equity | $180,881 | $191,165 | Condensed Statements of Operations Data (in thousands, except per share data) | | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Total revenue | $20,491 | $14,400 | | Gross profit | $18,007 | $12,342 | | Loss from operations | $(14,207) | $(8,453) | | Net loss | $(12,777) | $(8,521) | | Net loss per share (basic and diluted) | $(0.36) | $(1.56) | Condensed Statements of Cash Flows Data (in thousands) | | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(11,403) | $(9,550) | | Net cash used in investing activities | $(29,609) | $(132) | | Net cash provided by financing activities | $2 | $7,678 | | Net decrease in cash and cash equivalents | $(41,010) | $(2,004) | [Notes to Condensed Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Notes detail liquidity, revenue disaggregation, new debt facilities, and increased stock-based compensation for Q1 2025 - The company has incurred operating losses since inception, with an accumulated deficit of **$179.7 million** as of March 31, 2025, but management believes existing cash and cash equivalents of **$182.7 million** are sufficient to fund operations for at least the next **12 months**[30](index=30&type=chunk)[31](index=31&type=chunk)[32](index=32&type=chunk) Disaggregation of Revenue (in thousands) | Revenue Source | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | EEG headbands, point in time | $15,608 | $11,035 | | EEG portal and Clarity subscriptions, over time | $4,883 | $3,365 | | **Total Revenue** | **$20,491** | **$14,400** | - In February 2024, the company executed a Venture Loan and Security Agreement for a **$50 million** term loan commitment, drawing an initial **$20 million**, and secured a **$10 million** senior revolving line of credit[75](index=75&type=chunk)[76](index=76&type=chunk)[81](index=81&type=chunk) - Total stock-based compensation expense was **$2.3 million** for Q1 2025, a significant increase from **$0.8 million** in Q1 2024, primarily driven by higher expenses in general & administrative and sales & marketing functions[100](index=100&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=32&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses **42% revenue growth** driven by Ceribell System adoption, **55% operating expense increase**, and **$12.8 million net loss** for Q1 2025 [Overview](index=32&type=section&id=Overview) CeriBell's core Ceribell System, an AI-powered EEG platform, has expanded to over **550 active accounts** and served over **200,000 patients** - The company's core product is the **Ceribell System**, an **AI-powered**, point-of-care EEG platform designed for rapid diagnosis and continuous monitoring of neurological conditions in acute care settings[110](index=110&type=chunk)[112](index=112&type=chunk) - As of March 31, 2025, the company has expanded its customer base to over **550 active accounts** and its system has been used to care for over **200,000 patients**[111](index=111&type=chunk) - The company's primary commercial focus is the **U.S. market**, which has approximately **6,000 acute care facilities**, and it also holds a **CE Mark** for Europe with plans for further international expansion[113](index=113&type=chunk) [Results of Operations](index=39&type=section&id=Results%20of%20Operations) Q1 2025 revenue grew **42% to $20.5 million**, gross profit **46% to $18.0 million**, but operating expenses surged **55% to $32.2 million**, widening loss to **$14.2 million** Results of Operations Comparison (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Total revenue** | **$20,491** | **$14,400** | **$6,091** | **42%** | | Product revenue | $15,608 | $11,035 | $4,573 | 41% | | Subscription revenue | $4,883 | $3,365 | $1,518 | 45% | | **Gross profit** | **$18,007** | **$12,342** | **$5,665** | **46%** | | **Total operating expenses** | **$32,214** | **$20,795** | **$11,419** | **55%** | | Sales and marketing | $18,033 | $10,576 | $7,457 | 71% | | **Loss from operations** | **$(14,207)** | **$(8,453)** | **$(5,754)** | **68%** | | **Net loss** | **$(12,777)** | **$(8,521)** | **$(4,256)** | **50%** | - Revenue growth was driven by the addition of new customers and increased utilization of headbands by existing customers[134](index=134&type=chunk)[135](index=135&type=chunk) - The increase in operating expenses was primarily due to higher personnel-related costs from increased headcount, with sales and marketing expenses rising by **$7.5 million** (**71%**)[139](index=139&type=chunk)[140](index=140&type=chunk)[141](index=141&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity of **$182.7 million** from October 2024 IPO proceeds and new debt facilities is deemed sufficient for the next **12 months** - The company completed its IPO on **October 15, 2024**, receiving net proceeds of **$187.8 million**[149](index=149&type=chunk) - As of March 31, 2025, principal sources of liquidity consisted of **$182.7 million** in cash, cash equivalents, and short-term marketable securities[151](index=151&type=chunk) - Management believes existing cash and expected revenue will be sufficient to fund planned operating expenses and capital expenditure requirements for at least the next **12 months**[154](index=154&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=45&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company has determined that quantitative and qualitative disclosures about market risk are not applicable - The company has determined that quantitative and qualitative disclosures about market risk are not applicable[160](index=160&type=chunk) [Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were **effective** as of March 31, 2025[161](index=161&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[162](index=162&type=chunk) [PART II. OTHER INFORMATION](index=48&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=48&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any litigation expected to have a material adverse effect on its business - The company is not currently a party to any litigation that is expected to have a material adverse effect on its business[167](index=167&type=chunk) [Risk Factors](index=48&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant business, regulatory, and intellectual property risks, including a history of losses, dependence on a single product, intense competition, and complex healthcare compliance [Business and Industry Risk Factors](index=48&type=section&id=Business%20and%20Industry%20Risk%20Factors) Business risks include a history of net losses, dependence on the Ceribell System, intense competition, and reliance on Chinese manufacturers - The company has a history of net losses, incurring a loss of **$40.5 million** in fiscal year 2024, and expects to incur substantial losses in the foreseeable future[173](index=173&type=chunk) - The company faces competition from conventional EEG providers like **Natus** and **Nihon Kohden**, which have greater resources and brand recognition[180](index=180&type=chunk) - The company relies on manufacturers and suppliers in **China** for headband assembly and components, exposing it to foreign operational, political, and trade risks, including tariffs[184](index=184&type=chunk)[187](index=187&type=chunk)[188](index=188&type=chunk) [Risks Related to Regulatory Matters](index=64&type=section&id=Risks%20Related%20to%20Regulatory%20Matters) Regulatory risks involve uncertain third-party reimbursement, compliance with fraud and abuse laws, and stringent FDA regulations for medical devices - The ability to sell the Ceribell System profitably depends on adequate reimbursement from third-party payers, and the company's new Clarity algorithm received a New Technology Add-on Payment (**NTAP**) designation, which lasts for no more than **three years**[223](index=223&type=chunk)[224](index=224&type=chunk) - The company is subject to numerous federal and state healthcare fraud and abuse laws, including the **Anti-Kickback Statute** and **False Claims Act**, which constrain business and marketing practices[233](index=233&type=chunk)[236](index=236&type=chunk) - Products are regulated as medical devices by the **FDA** and require marketing authorization (e.g., **510(k) clearance**), and any modifications may require new submissions, with adherence to the **Quality System Regulation (QSR)** for manufacturing[248](index=248&type=chunk)[254](index=254&type=chunk)[273](index=273&type=chunk) [Risks Related to Our Intellectual Property](index=100&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) IP risks include protecting patents and trade secrets, potential infringement litigation, and dependence on an in-license from Stanford University - The company's success depends on its ability to obtain, maintain, and enforce its intellectual property rights, including **patents, trademarks, and trade secrets**[332](index=332&type=chunk) - The company may become party to **expensive and time-consuming** intellectual property litigation, and could be forced to cease commercializing products or pay substantial damages if found to be infringing on third-party rights[359](index=359&type=chunk)[361](index=361&type=chunk) - The company's "brain stethoscope" EEG sonification technology is protected by intellectual property rights in-licensed from **Stanford University**, and the business is subject to compliance with the terms of this license agreement[370](index=370&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=134&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity sales occurred; IPO proceeds of **$188.2 million** are used for sales, R&D, and general corporate purposes - On October 15, 2024, the company completed its IPO, receiving net proceeds of approximately **$188.2 million**[437](index=437&type=chunk) - The IPO proceeds are being used to fund sales and marketing, research and product development, and for general corporate purposes, with no material change from the intended use described in the prospectus[438](index=438&type=chunk)[439](index=439&type=chunk) [Defaults Upon Senior Securities](index=134&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon its senior securities - None[440](index=440&type=chunk) [Mine Safety Disclosures](index=134&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not applicable[441](index=441&type=chunk) [Other Information](index=134&type=section&id=Item%205.%20Other%20Information) This section details the adoption and termination of Rule 10b5-1 trading plans by company executives in March 2025 Rule 10b5-1 Trading Plans Activity | Name | Action | Date | Total Shares to be Sold | | :--- | :--- | :--- | :--- | | David Foehr | Terminate | Mar 4, 2025 | 17,223 | | David Foehr | Adopt | Mar 11, 2025 | 15,071 | | Scott Blumberg | Adopt | Mar 14, 2025 | 93,000 | | Rebecca Robertson | Adopt | Mar 14, 2025 | 40,426 | [Exhibits](index=136&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents and officer certifications - The report includes several exhibits, such as corporate governance documents, a separation agreement with Joshua Copp dated March 28, 2025, and required officer certifications[446](index=446&type=chunk)

[Ceribell First Quarter 2025 Financial Results](index=1&type=section&id=Ceribell%20First%20Quarter%202025%20Financial%20Results) [First Quarter 2025 & Recent Highlights](index=1&type=section&id=First%20Quarter%202025%20%26%20Recent%20Highlights) Ceribell achieved a strong start to 2025 with **42% revenue growth** to **$20.5 million**, expanding its active accounts and securing key regulatory approvals - CEO Jane Chao emphasized a strong start to the year, driven by expanded accounts and accelerated system adoption, with plans for continued growth to establish EEG as a new vital sign[3](index=3&type=chunk) - Ending the quarter with **558 total active accounts**[9](index=9&type=chunk) - Received U.S. FDA 510(k) clearance for the Clarity™ algorithm for patients aged 1 and older[9](index=9&type=chunk) - Became the first medical device company to receive FedRAMP High authorization from the U.S. federal government[9](index=9&type=chunk) Q1 2025 Key Financial Metrics | Metric | Value ($) | Change (YoY, %) | | :--- | :--- | :--- | | Total Revenue | $20.5 million | +42% | | Gross Margin | 88% | N/A | [First Quarter 2025 Financial Results](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results) Ceribell's Q1 2025 revenue grew **42% to $20.5 million** with an **88% gross margin**, but increased operating expenses led to a **$12.8 million net loss** Q1 2025 vs Q1 2024 Revenue Breakdown | Revenue Type | Q1 2025 ($) | Q1 2024 ($) | Growth (%) | | :--- | :--- | :--- | :--- | | Product Revenue | $15.6 million | $11.0 million | +41% | | Subscription Revenue | $4.9 million | $3.4 million | +45% | | **Total Revenue** | **$20.5 million** | **$14.4 million** | **+42%** | Q1 2025 vs Q1 2024 Profitability | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Gross Profit ($) | $18.0 million | $12.3 million | | Gross Margin (%) | 88% | 86% | - Operating expenses increased by **55% to $32.2 million** from **$20.8 million** in Q1 2024, primarily due to investments in the commercial organization, increased headcount, and public company operating costs[6](index=6&type=chunk) Q1 2025 Net Loss and Cash Position | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Loss ($) | $12.8 million | $8.5 million | | Net Loss Per Share ($) | $0.36 | $1.56 | | **As of March 31, 2025** | | | | Cash, cash equivalents, and marketable securities ($) | $182.7 million | N/A | [2025 Financial Outlook](index=1&type=section&id=2025%20Financial%20Outlook) Ceribell raised its full-year 2025 revenue guidance to **$83 million to $87 million**, reflecting an anticipated **27% to 33% growth** - The company raised its full-year 2025 revenue guidance to a range of **$83 million to $87 million**[8](index=8&type=chunk) - The updated guidance represents an expected revenue growth of approximately **27% to 33%** over the prior year[8](index=8&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) Unaudited condensed financial statements for Ceribell, Inc. as of March 31, 2025, detail the quarter's operations and balance sheet position [Condensed Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Ceribell's Q1 2025 operations show **total revenue of $20.49 million** and a **net loss of $12.78 million** due to increased operating expenses Condensed Statement of Operations (in thousands) | Account | Three months ended March 31, 2025 (in thousands) | Three months ended March 31, 2024 (in thousands) | | :--- | :--- | :--- | | Total revenue | $20,491 | $14,400 | | Gross profit | $18,007 | $12,342 | | Total operating expenses | $32,214 | $20,795 | | Loss from operations | $(14,207) | $(8,453) | | Net loss | $(12,777) | $(8,521) | | Net loss per share | $(0.36) | $(1.56) | [Condensed Balance Sheets](index=5&type=section&id=Condensed%20Balance%20Sheets) As of March 31, 2025, Ceribell's balance sheet reflects **total assets of $213.47 million** and **stockholders' equity of $180.88 million** Condensed Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $153,360 | $194,370 | | Total current assets | $205,420 | $217,272 | | Total assets | $213,471 | $225,412 | | Total liabilities | $32,590 | $34,247 | | Total stockholders' equity | $180,881 | $191,165 | [Other Information](index=2&type=section&id=Other%20Information) Logistical and legal information, including investor call details, forward-looking statements, and a corporate overview, are provided [Webcast and Conference Call Details](index=2&type=section&id=Webcast%20and%20Conference%20Call%20Details) A conference call and webcast for Q1 2025 financial results were scheduled for May 8, 2025, at **1:30 p.m. PT** - A conference call to discuss Q1 2025 results was scheduled for May 8, 2025, at **1:30 p.m. PT**, with access via phone and a webcast available on the company's investor relations website[10](index=10&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) The release contains forward-looking statements subject to substantial risks and uncertainties, with actual results potentially differing materially - The release contains forward-looking statements concerning financial guidance, business strategy, and product expectations, which are subject to substantial risks and uncertainties[11](index=11&type=chunk) - Key risks include limited operating history, market adoption challenges, competitive pressures, manufacturing dependencies in China, and regulatory compliance[11](index=11&type=chunk) [About CeriBell, Inc.](index=2&type=section&id=About%20CeriBell%2C%20Inc.) Ceribell is a medical technology company providing an FDA-cleared, AI-powered point-of-care EEG system for rapid neurological diagnosis - Ceribell is a medical technology company that developed the Ceribell System, a point-of-care electroencephalography (EEG) platform for use in acute care settings[12](index=12&type=chunk) - The system combines portable hardware with AI-powered algorithms to enable rapid diagnosis and continuous monitoring of patients with suspected seizure activity[12](index=12&type=chunk)